Literature DB >> 36243846

PI3K Isoforms in CD8+ T Cell Development and Function.

Pankaj Gaur1, Mikayel Mkrtichyan1, Vivek Verma1, Nazli Jafarzadeh1, Mariana Hattar1, Seema Gupta1, Samir N Khleif2.   

Abstract

CD8+ T cells are an essential part of the immune system and play a vital role in defending against tumors and infections. The phosphoinositide-3-kinase (PI3K), especially class I, is involved in numerous interrelated signaling pathways which control CD8+ T cell development, maturation, migration, activation, and differentiation. While CD8+ T lymphocytes express all class I PI3K isoforms (PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ), isoform-specific functions, especially for PI3Kα and PI3Kβ have not been fully elucidated. A few studies suggest the important role of p110δ and p110γ in CD8+ T cell activation, signaling, chemotaxis and function and several clinical trials are currently testing the effect of isoform-specific inhibitors in various types of cancers, including Indolent Non-Hodgkin Lymphoma, Peripheral T cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, non-small cell lung carcinoma (NSCLC), head & neck cancer, and breast cancer. This chapter summarizes current knowledge of the roles of various PI3K isoforms and downstream signaling pathways in regulating CD8+ T cell fate, including cell proliferation, migration, and memory generation. We also discuss certain clinical trials employing PI3K inhibitors for cancer therapy, their limitations, and future perspectives.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  CD8+ T cell; Memory; Migration; PI3K signaling; PI3Kγ; PI3Kδ; Survival

Mesh:

Substances:

Year:  2022        PMID: 36243846     DOI: 10.1007/978-3-031-06566-8_9

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.737


  65 in total

Review 1.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

2.  Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition.

Authors:  Rasha Abu Eid; Shamim Ahmad; Yuan Lin; Mason Webb; Zuzana Berrong; Rajeev Shrimali; Takumi Kumai; Sudha Ananth; Paulo C Rodriguez; Esteban Celis; John Janik; Mikayel Mkrtichyan; Samir N Khleif
Journal:  Cancer Res       Date:  2017-06-14       Impact factor: 12.701

3.  Akt fine-tunes NF-κB-dependent gene expression during T cell activation.

Authors:  Jing Cheng; Binh Phong; David C Wilson; Raphael Hirsch; Lawrence P Kane
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

Review 4.  Telomerase and primary T cells: biology and immortalization for adoptive immunotherapy.

Authors:  Eugene V Barsov
Journal:  Immunotherapy       Date:  2011-03       Impact factor: 4.196

5.  A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner.

Authors:  Nilesh M Dagia; Gautam Agarwal; Divya V Kamath; Anshu Chetrapal-Kunwar; Ravindra D Gupte; Mahesh G Jadhav; Shruta S Dadarkar; Jacqueline Trivedi; Asha A Kulkarni-Almeida; Firuza Kharas; Lyle C Fonseca; Sanjay Kumar; Mandar R Bhonde
Journal:  Am J Physiol Cell Physiol       Date:  2010-01-20       Impact factor: 4.249

6.  Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

Authors:  Olivier De Henau; Matthew Rausch; David Winkler; Luis Felipe Campesato; Cailian Liu; Daniel Hirschhorn Cymerman; Sadna Budhu; Arnab Ghosh; Melissa Pink; Jeremy Tchaicha; Mark Douglas; Thomas Tibbitts; Sujata Sharma; Jennifer Proctor; Nicole Kosmider; Kerry White; Howard Stern; John Soglia; Julian Adams; Vito J Palombella; Karen McGovern; Jeffery L Kutok; Jedd D Wolchok; Taha Merghoub
Journal:  Nature       Date:  2016-11-09       Impact factor: 49.962

7.  Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8+ T-cell proliferation and survival.

Authors:  Rasha Abu Eid; Kevin M Friedman; Mikayel Mkrtichyan; Andrea Walens; William King; John Janik; Samir N Khleif
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

8.  PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity.

Authors:  Larissa S Carnevalli; Charles Sinclair; Molly A Taylor; Pablo Morentin Gutierrez; Sophie Langdon; Anna M L Coenen-Stass; Lorraine Mooney; Adina Hughes; Laura Jarvis; Anna Staniszewska; Claire Crafter; Ben Sidders; Elizabeth Hardaker; Kevin Hudson; Simon T Barry
Journal:  J Immunother Cancer       Date:  2018-12-27       Impact factor: 13.751

9.  mTOR regulates memory CD8 T-cell differentiation.

Authors:  Koichi Araki; Alexandra P Turner; Virginia Oliva Shaffer; Shivaprakash Gangappa; Susanne A Keller; Martin F Bachmann; Christian P Larsen; Rafi Ahmed
Journal:  Nature       Date:  2009-06-21       Impact factor: 49.962

10.  A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.

Authors:  Maria I Carlo; Ana M Molina; Yulia Lakhman; Sujata Patil; Kaitlin Woo; John DeLuca; Chung-Han Lee; James J Hsieh; Darren R Feldman; Robert J Motzer; Martin H Voss
Journal:  Oncologist       Date:  2016-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.